ZD 7114 hydrochlorideCAS# 129689-28-7 |
2D Structure
- ML 141
Catalog No.:BCC8092
CAS No.:71203-35-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 129689-28-7 | SDF | Download SDF |
PubChem ID | 9890216 | Appearance | Powder |
Formula | C22H31ClN2O6 | M.Wt | 454.95 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | ICI D7114 | ||
Solubility | Soluble to 100 mM in DMSO | ||
Chemical Name | 2-[4-[2-[[(2S)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]-N-(2-methoxyethyl)acetamide;hydrochloride | ||
SMILES | COCCNC(=O)COC1=CC=C(C=C1)OCCNCC(COC2=CC=CC=C2)O.Cl | ||
Standard InChIKey | KCAMZVQSGDBGGF-FERBBOLQSA-N | ||
Standard InChI | InChI=1S/C22H30N2O6.ClH/c1-27-13-12-24-22(26)17-30-21-9-7-20(8-10-21)28-14-11-23-15-18(25)16-29-19-5-3-2-4-6-19;/h2-10,18,23,25H,11-17H2,1H3,(H,24,26);1H/t18-;/m0./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | β3-adrenoceptor agonist. Active metabolite ICI 215,001 hydrochloride also available. |
ZD 7114 hydrochloride Dilution Calculator
ZD 7114 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.198 mL | 10.9902 mL | 21.9804 mL | 43.9609 mL | 54.9511 mL |
5 mM | 0.4396 mL | 2.198 mL | 4.3961 mL | 8.7922 mL | 10.9902 mL |
10 mM | 0.2198 mL | 1.099 mL | 2.198 mL | 4.3961 mL | 5.4951 mL |
50 mM | 0.044 mL | 0.2198 mL | 0.4396 mL | 0.8792 mL | 1.099 mL |
100 mM | 0.022 mL | 0.1099 mL | 0.2198 mL | 0.4396 mL | 0.5495 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3,4-Dihydroxybisabola-1,10-diene
Catalog No.:BCN7326
CAS No.:129673-87-6
- 3-Hydroxybisabola-1,10-dien-9-one
Catalog No.:BCN7325
CAS No.:129673-86-5
- GR 82334
Catalog No.:BCC5802
CAS No.:129623-01-4
- Nevirapine
Catalog No.:BCC3820
CAS No.:129618-40-2
- Satraplatin
Catalog No.:BCC5356
CAS No.:129580-63-8
- Goniopypyrone
Catalog No.:BCN3957
CAS No.:129578-07-0
- Tolfenpyrad
Catalog No.:BCC8069
CAS No.:129558-76-5
- Verteporfin
Catalog No.:BCC3690
CAS No.:129497-78-5
- 3,4-Diacetoxycinnamamide
Catalog No.:BCN6157
CAS No.:129488-34-2
- Fmoc-Asp-OtBu
Catalog No.:BCC3088
CAS No.:129460-09-9
- Fulvestrant
Catalog No.:BCC1081
CAS No.:129453-61-8
- Boc-Cysteinol(pMeBzl)
Catalog No.:BCC3044
CAS No.:129397-85-9
- Dofequidar
Catalog No.:BCC4176
CAS No.:129716-58-1
- Aripiprazole
Catalog No.:BCC5034
CAS No.:129722-12-9
- 2',4'-Dihydroxy-3',6'-dimethoxychalcone
Catalog No.:BCN6158
CAS No.:129724-43-2
- 3-Hydroxylanost-9(11)-24-dien-26-oic acid
Catalog No.:BCN1586
CAS No.:129724-83-0
- Anemoside A3
Catalog No.:BCN2328
CAS No.:129724-84-1
- Anemoside B4
Catalog No.:BCN1276
CAS No.:129741-57-7
- ODM-201
Catalog No.:BCC3796
CAS No.:1297538-32-9
- MC 976
Catalog No.:BCC1734
CAS No.:129831-99-8
- Amicarbazone
Catalog No.:BCC5464
CAS No.:129909-90-6
- Dapoxetine HCl
Catalog No.:BCC5064
CAS No.:129938-20-1
- Iloperidone hydrochloride
Catalog No.:BCC4212
CAS No.:1299470-39-5
- Senecionine
Catalog No.:BCN2129
CAS No.:130-01-8
Effects of ZD7114, a selective beta3-adrenoceptor agonist, on neuroendocrine mechanisms controlling energy balance.[Pubmed:9653893]
Eur J Pharmacol. 1998 Apr 24;347(2-3):265-74.
Selective beta3-adrenoceptor agonists increase energy expenditure by increasing non-shivering thermogenesis in brown adipose tissue. The aim of this study was to investigate how changes in energy balance affect energy intake and interaction of peripheral metabolic feedback signals with central neuroendocrine mechanisms participating in the control of body energy balance. Expression of preproneuropeptide Y (preproNPY) mRNA in the arcuate nucleus and preprocorticotropin-releasing factor (CRF) mRNA in the paraventricular nucleus were measured by in situ hybridisation technique after 1 day, 1 and 5 weeks of treatment with ZD7114 ((S)-4-[2-[(2-hydroxy-3-phenoxypropyl)amino]ethoxy]-N-(2-methoxyet hyl)phenoxyacetamide, 3 mg kg(-1) day(-1) in drinking water) in obese fa/fa Zucker rats. In addition, expression of leptin mRNA in epididymal fat and serum levels of leptin were analysed. Food intake, body weights, binding of GDP to brown adipose tissue mitochondria, plasma insulin and glucose were also measured. Treatment with ZD7114 significantly reduced weight gain and activated brown adipose tissue thermogenesis, but had no effect on food intake. Expressions of preproNPY or preproCRF mRNAs were similarly not changed by treatment with ZD7114. Furthermore, ZD7114 had no effect on plasma insulin or leptin and the expression of leptin mRNA in epididymal fat. However, statistically significant correlations were found between preproNPY and preproCRF mRNA expressions and brown fat thermogenic activity and plasma insulin levels in the ZD7114 treated rats, but not in the control rats. It is concluded that treatment with ZD7114 markedly activated brown fat thermogenesis, but did not affect neuropeptide Y (NPY) and CRF gene expression per se. However, the correlation analyses suggest that ZD7114 may modulate feedback connections of brown adipose tissue thermogenesis and plasma insulin with the hypothalamic neuroendocrine mechanisms integrating body energy balance.
Evaluation of ICI D7114, a putative stimulant of brown adipocytes, on histamine-contracted guinea-pig ileum.[Pubmed:8104647]
Br J Pharmacol. 1993 Aug;109(4):1212-8.
1. Experiments were performed to characterize the effects of the novel brown adipocyte stimulant, ICI D7114, in the guinea-pig isolated ileum, right atrium and tracheal chain. In the ileum, agonist-induced inhibition of the contractile response to either histamine or prostaglandin E2 (PGE2) was assessed, along with effects on resting rate in the atrium and resting tone in the tracheal chain. In the latter two preparations, antagonism of isoprenaline-induced responses by ICI D7114 was also assessed. 2. Inhibitory responses were obtained in the ileum to ICI D7114, isoprenaline, BRL37344, and noradrenaline. The responses to ICI D7114, isoprenaline and BRL37344 were resistant to blockade with propranolol (5 microM), naloxone (1 microM), methysergide (0.1 microM), cimetidine, indomethacin and 8-phenyltheophylline (all 10 microM). These responses to isoprenaline, in the presence of propranolol (5 microM), were competitively antagonized by alprenolol (1-100 microM) with a pA2 value of 6.44. The responses to ICI D7114 and BRL37344 were antagonized by single concentrations of alprenolol (1 microM) with apparent pKB values of 6.53 and 6.57 respectively. These data indicate an effect of ICI D7114 at the atypical beta-adrenoceptor in the guinea-pig ileum. 3. The order and relative potency of agonists at the atypical beta-adrenoceptor was BRL37344 (4) < isoprenaline (1) = ICI D7114 (1.1) > noradrenaline (0.5). 4. ICI D7114 (1 nM - 10 microM) caused no significant change in the rate of beating or the resting tone of the guinea-pig right atrium or tracheal chain respectively. It did, however, cause selective blockade of the responses to isoprenaline in these tissues (apparent pKB values 7.63 and 5.85 in atrium and tracheal chain respectively). Responses to histamine (atrium) and aminophylline (tracheal chain) were not significantly affected by 10 microM ICI D7114.5. These results demonstrate that ICI D7114 possesses selective agonist activity at atypical beta-adrenoceptors in the guinea-pig ileum and its use as a tool may help to establish a role for the atypical beta-adrenoceptor in the control of gastrointestinal motility.